1. Behl, Tapan, Kaur, Ishnoor, Kumar, Arun, Zengin, Gokhan, Arora, Sandeep. . Gene Therapy in the Management of Parkinson's Disease: Potential of GDNF as a Promising Therapeutic Strategy. In Current gene therapy, 20, 207-222. doi:10.2174/1566523220999200817164051. https://pubmed.ncbi.nlm.nih.gov/32811394/
2. Kirik, Deniz, Cederfjäll, Erik, Halliday, Glenda, Petersén, Åsa. 2016. Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. In Neurobiology of disease, 97, 179-188. doi:10.1016/j.nbd.2016.09.008. https://pubmed.ncbi.nlm.nih.gov/27616425/
3. Even Ram, Sharona, Galun, Eithan. . AAV2-GDNF gene therapy for Parkinson's disease. In Human gene therapy, 20, 430-1. doi:10.1089/hum.2009.1599. https://pubmed.ncbi.nlm.nih.gov/19438403/
4. Eggers, Ruben, de Winter, Fred, Hoyng, Stefan A, Tannemaat, Martijn R, Verhaagen, Joost. . Timed GDNF gene therapy using an immune-evasive gene switch promotes long distance axon regeneration. In Brain : a journal of neurology, 142, 295-311. doi:10.1093/brain/awy340. https://pubmed.ncbi.nlm.nih.gov/30649249/
5. Das, Arundhuti, Pagliaroli, Luca, Vereczkei, Andrea, Demetrovics, Zsolt, Barta, Csaba. 2019. Association of GDNF and CNTNAP2 gene variants with gambling. In Journal of behavioral addictions, 8, 471-478. doi:10.1556/2006.8.2019.40. https://pubmed.ncbi.nlm.nih.gov/31446765/
6. Nanobashvili, Avtandil, Melin, Esbjörn, Emerich, Dwaine, Wahlberg, Lars, Kokaia, Merab. 2018. Unilateral ex vivo gene therapy by GDNF in epileptic rats. In Gene therapy, 26, 65-74. doi:10.1038/s41434-018-0050-7. https://pubmed.ncbi.nlm.nih.gov/30464254/